5J2 Stock Chart & Stats
€0.01
>-€0.01(-5.13%)
At close: 4:00 PM EST
€0.01
>-€0.01(-5.13%)
Day’s Range― - ―
52-Week Range€0.00 - €0.02
Previous CloseN/A
Volume0.00
Average Volume (3M)1.71K
Market Cap
€1.66M
Enterprise Value€17.27
Total Cash (Recent Filing)€6.04M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta2.97
Next Earnings
Aug 27, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding610,491,300
10 Day Avg. Volume1,710
30 Day Avg. Volume1,710
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-6.10
Price to Sales (P/S)0.00
P/FCF Ratio-0.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageNo reported debt lowers fixed financing obligations and preserves flexibility to fund R&D or clinical programs via equity or milestone financing. For a pre-revenue specialty drug developer this durable advantage extends runway and reduces short-term default risk versus leveraged peers.
Narrowing Operating LossesA sustained reduction in EBIT losses over multiple years signals improving operating efficiency and cost discipline. Narrowing losses lengthen the effective runway per financing round and improve the firm's ability to advance programs without proportional increases in burn, a durable operational improvement.
Improved Equity CushionAn increase in trailing equity and assets reflects recapitalization that strengthens solvency and reduces immediate insolvency risk. A repaired balance sheet gives management greater optionality for partnerships, R&D spend, or staged financing over the coming months.
Bears Say
Zero RevenueA multi-year pre-revenue profile means no product-market cash inflows to offset costs. Without operating revenue, the company cannot self-fund growth, increasing reliance on external capital and heightening dilution and execution risk over the medium term.
Persistent Negative Free Cash FlowConsistently negative free cash flow demonstrates ongoing cash burn that depletes reserves and forces repeated financing. Persistent FCF deficits constrain strategic choices, limit internal investment capacity, and increase vulnerability if capital markets tighten.
History Of Negative EquityEpisodes of negative shareholders' equity indicate accumulated losses and past recapitalization needs. Such a history weakens creditor and partner confidence, can limit funding alternatives, and signals elevated solvency risk if operating performance stalls.
5J2 FAQ
What was Gabather AB’s price range in the past 12 months?
Gabather AB lowest stock price was €0.00 and its highest was €0.01 in the past 12 months.
What is Gabather AB’s market cap?
Gabather AB’s market cap is €1.66M.
When is Gabather AB’s upcoming earnings report date?
Gabather AB’s upcoming earnings report date is Aug 27, 2026 which is in 22 days.
How were Gabather AB’s earnings last quarter?
Gabather AB released its earnings results on May 28, 2026. The company reported €0 earnings per share for the quarter, the consensus estimate of €0 by €0.
Is Gabather AB overvalued?
According to Wall Street analysts Gabather AB’s price is currently Overvalued.
Does Gabather AB pay dividends?
Gabather AB does not currently pay dividends.
What is Gabather AB’s EPS estimate?
Gabather AB’s EPS estimate is 0.
How many shares outstanding does Gabather AB have?
Gabather AB has 610,491,300 shares outstanding.
What happened to Gabather AB’s price movement after its last earnings report?
Gabather AB reported an EPS of €0 in its last earnings report, expectations of €0. Following the earnings report the stock price went down -33.333%.
Which hedge fund is a major shareholder of Gabather AB?
Currently, no hedge funds are holding shares in DE:5J2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Gabather AB
Gabather AB (publ) is dedicated to creating innovative pharmaceutical solutions for a range of central nervous system disorders. The company's focus includes developing medications for conditions such as psychotic illnesses, mood and anxiety disorders, pain relief, and cognitive function enhancement, notably those related to Alzheimer's disease. Founded in 2014, its operations are headquartered in Södertälje, Sweden.
AlzeCure Pharma AB
―
Vivesto AB
―
Klaria Pharma Holding AB
―
Nanexa AB
―
Enorama Pharma AB
―